Company news
Lexaria Bioscience Corp. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Lexaria Provides Annual Letter From the CEO
January 26, 2022
Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4
December 28, 2021
Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
December 15, 2021
Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion
December 13, 2021
Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2
December 7, 2021
Lexaria Bioscience Corp. Announces Participation in the Benzinga Global Small Cap Conference
December 5, 2021
Lexaria Announces Ambitious New Hypertension Study HYPER-H21-4
November 2, 2021
Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol
October 31, 2021
Lexaria's Technology Proven to Deliver Oral THC More Effectively
October 12, 2021
Lexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results
October 4, 2021
Lexaria Takes Another Step Towards NDA Filing for DehydraTECH- CBD
September 13, 2021
Lexaria Begins Investigational New Drug (IND) Enabling Program for DehydraTECH-CBD for Hypertension
September 7, 2021
Lexaria's Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory Period
September 6, 2021
Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2
July 26, 2021
Lexaria Receives US$3,817,643 From Warrant Exercises
July 25, 2021
Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3
July 20, 2021
Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada's National Research Council
July 14, 2021
Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets
July 4, 2021
Lexaria Announces 2021 Annual Meeting Results
June 28, 2021
Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)
June 16, 2021
Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs
June 14, 2021
Lexaria Provides Progress Report on Six R&D Programs
June 8, 2021
Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1
June 6, 2021
Lexaria DehydraTECH(TM) 2.0 Outperforms MCT in 2021 R&D Study
May 24, 2021
Lexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever
May 19, 2021
Lexaria Strengthens Its International Patent Portfolio to 19 Patents Granted
May 11, 2021
Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1
May 5, 2021
Lexaria Commences Human Clinical Hypertension Study
April 21, 2021
Lexaria Appoints New Chief Financial Officer and Issues Consultant Warrants
April 14, 2021
Lexaria to Evaluate DehydraTECH(TM) in Multiple New Markets
April 5, 2021
Lexaria Technology Generates Positive Stability Testing for World-Class Ready-to-Drink CBD Beverages
March 23, 2021
Lexaria to Present and Meet with Investors One-on-One at the 33rd Annual Virtual ROTH Conference on March 15-17, 2021
March 10, 2021
Lexaria Expands R&D Program to Address US$28 Billion Hypertension Market with Addition of Two Human Clinical Studies
February 10, 2021
Lexaria Appoints New Board Member
January 14, 2021
Lexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering
January 11, 2021
Decks
- Investor Presentation (December 2020)
Investor deck · 30 slides · Dec 31, 2020
- Investor Presentation (July 2019)
Investor deck · 27 slides · July 2019
- Investor Presentation (November 2017)
Investor deck · 16 slides · Nov 2, 2017